Cargando…
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
INTRODUCTION: PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α) somatic mutations are the most common genetic alteration in breast cancer (BC). Their prognostic value and that of the phosphatidylinositol 3-kinase (PI3K) pathway in BC remains only partly defined. The effect...
Autores principales: | López-Knowles, Elena, Segal, Corrinne V, Gao, Qiong, Garcia-Murillas, Isaac, Turner, Nicholas C, Smith, Ian, Martin, Lesley-Ann, Dowsett, Mitch |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227109/ https://www.ncbi.nlm.nih.gov/pubmed/24981670 http://dx.doi.org/10.1186/bcr3683 |
Ejemplares similares
-
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations
por: Lopez-Knowles, Elena, et al.
Publicado: (2018) -
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment
por: Schuster, Eugene F., et al.
Publicado: (2019) -
PIK3CA mutation enrichment and quantitation from blood and tissue
por: Keraite, Ieva, et al.
Publicado: (2020) -
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019) -
Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)